Mounjaro (tirzepatide): trademark, dual GIP/GLP-1, and the RUO molecule

Educational material about research-use reagents; not instructions for human use.

A search for Mounjaro usually means the prescription brand (Mounjaro, Zepbound), not INN tirzepatide on an RUO vial. Tirzepatide acts on two axes: GLP-1 + GIP (dual incretin agonist). The triple axis with glucagon is covered separately for retatrutide on Tripept.

Mounjaro and the tirzepatide molecule

Mounjaro/Zepbound are finished drug products with fixed dosing and regulatory status. Tirzepatide (INN) in the research catalog is a separate entity: lyophilized material with COA per LOT, Research Use Only. The Longeva hub does not sell Mounjaro; the Incretin brand context is tirzepatide RUO.

Dual vs GLP-1-only

Semaglutide activates mainly the GLP-1 receptor; tirzepatide adds the GIP axis. Compare with Ozempic: Mounjaro vs Ozempic. Three-axis map: GLP-1, GIP and glucagon.

COA and counterfeits

When sourcing RUO material, match the LOT to the PDF in the COA archive. A marketplace brand name without COA does not prove tirzepatide identity.

Hub editorial only · Incretin = canonical GLP-1/GIP commerce · Tripept = retatrutide triple class.